News

Life Technologies said that the pilot study builds upon a research trial announced earlier this year in association with TGen and US Oncology, to sequence the genomes of

Under the terms of the agreement, Perceptive Imagineering will represent RPC and conduct product registration, marketing, sales and support for the licensing and distribution of Onko-Sure as a

Under the terms of the agreement, Oramed will out-license technology to Entera for the development of oral delivery drugs for certain indications. The out-licensed technology differs from Oramed’s

China Nuokang has posted a net income of RMB17.07m, or RMB0.11 per diluted share, compared to RMB11.19m, or RMB0.05 per diluted share, for the prior year period. Operating

The sales for Protidiet increased compared to the same quarter of 2009 due to the higher demand for Ranaz’s products in US. The sales for ProtiLife decreased, compared

Sinovac said that, as part of the bidding process, the Beijing CDC will evaluate potential suppliers and assigns scores for different factors, including product quality, service and price.

The option to license the breast cancer vaccine technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune. Reportedly, upon IND

According to Amgen, Prolia’s approval is based on a pivotal three-year Phase 3 study involving 7,808 postmenopausal women with osteoporosis. Amgen claimed that Prolia, the first and only

YAZ is a progesterone and estrogen combination birth control pill. Yaz is used for preventing pregnancy. Teva Pharma has claimed that, as the first company to file an